LU92218I9 - - Google Patents

Info

Publication number
LU92218I9
LU92218I9 LU92218C LU92218C LU92218I9 LU 92218 I9 LU92218 I9 LU 92218I9 LU 92218 C LU92218 C LU 92218C LU 92218 C LU92218 C LU 92218C LU 92218 I9 LU92218 I9 LU 92218I9
Authority
LU
Luxembourg
Prior art keywords
bladder
rat
urination
rhythmic
measurement test
Prior art date
Application number
LU92218C
Other languages
English (en)
Other versions
LU92218I2 (fr
Inventor
Toshiyuki Takasu
Shuichi Sato
Masashi Ukai
Tatsuya Maruyama
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32310425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92218(I9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of LU92218I2 publication Critical patent/LU92218I2/fr
Publication of LU92218I9 publication Critical patent/LU92218I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU92218C 2002-11-07 2013-06-17 Mirabegron ou un de ses sels LU92218I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002323792 2002-11-07

Publications (2)

Publication Number Publication Date
LU92218I2 LU92218I2 (fr) 2014-01-07
LU92218I9 true LU92218I9 (fr) 2019-01-17

Family

ID=32310425

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92218C LU92218I2 (fr) 2002-11-07 2013-06-17 Mirabegron ou un de ses sels

Country Status (28)

Country Link
US (5) USRE44872E1 (fr)
EP (1) EP1559427B1 (fr)
JP (1) JP3815496B2 (fr)
KR (1) KR100967070B1 (fr)
CN (1) CN100406011C (fr)
AT (1) ATE500827T1 (fr)
AU (1) AU2003284700B2 (fr)
BE (1) BE2013C040I2 (fr)
BR (1) BR0316080A (fr)
CA (1) CA2503570C (fr)
CY (2) CY1111399T1 (fr)
DE (1) DE60336334D1 (fr)
DK (1) DK1559427T3 (fr)
ES (1) ES2360353T3 (fr)
FR (1) FR13C0032I2 (fr)
HU (1) HUS1300027I1 (fr)
IL (1) IL168121A (fr)
LU (1) LU92218I2 (fr)
MX (1) MXPA05004925A (fr)
NL (1) NL300599I2 (fr)
NO (2) NO334948B1 (fr)
NZ (1) NZ539577A (fr)
PL (1) PL211687B1 (fr)
PT (1) PT1559427E (fr)
RU (1) RU2321401C2 (fr)
SI (1) SI1559427T1 (fr)
WO (1) WO2004041276A1 (fr)
ZA (1) ZA200503510B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
PL2216021T3 (pl) * 2007-11-02 2013-03-29 Astellas Pharma Inc Kompozycja farmaceutyczna do leczenia zespołu pęcherza nadreaktywnego
EP2223690A4 (fr) * 2007-12-21 2011-02-23 Astellas Pharma Inc Composition pharmaceutique utilisée pour atténuer les symptômes du tractus urinaire inférieur
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2363397A4 (fr) * 2008-11-07 2012-07-11 Dainippon Sumitomo Pharma Co Nouvel agent thérapeutique utile pour un symptôme du tractus urinaire inférieur
US8586760B2 (en) 2009-06-15 2013-11-19 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
US8877214B2 (en) 2010-03-29 2014-11-04 Astellas Pharma Inc. Pharmaceutical composition for modified release
TR201802207T4 (tr) 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
WO2012156998A2 (fr) * 2011-05-18 2012-11-22 Dr. Reddy's Laboratories Limited Mirabegron amorphe et procédés de préparation de formes cristallines de mirabegron
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
WO2013147134A1 (fr) 2012-03-30 2013-10-03 アステラス製薬株式会社 Composition pharmaceutique contenant du mirabegron
CN104602693A (zh) 2012-08-31 2015-05-06 安斯泰来制药株式会社 口服给药用药物组合物
WO2014132270A2 (fr) * 2013-02-27 2014-09-04 Msn Laboratories Limited Procédé de préparation de monochlorydrate d'acétamide 2- (2-aminothiazol -4-yl)-n- [4- (2- {[ (2r) -2-hydroxy -2-phényl-éthyl] amino} éthyl) phényl], de ses intermédiaires et polymorphe de celui-ci
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103193658A (zh) * 2013-04-18 2013-07-10 苏州永健生物医药有限公司 一种（r）-2-对硝基苯乙胺基-1-苯乙醇及其盐的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
CA2919198A1 (fr) * 2013-07-23 2015-01-29 Allergan, Inc. Methodes et compositions comprenant de la desmopressine combinee a un agoniste du recepteur adrenergique beta-3
ITMI20131653A1 (it) * 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
RU2550968C1 (ru) * 2013-11-29 2015-05-20 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем
WO2015155664A1 (fr) * 2014-04-08 2015-10-15 Suven Life Sciences Limited Procédé amélioré de préparation de 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2-phényléthyl] amino]-éthyl)phényl]acétamide
WO2015162536A1 (fr) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Nouveau procédé de préparation de mirabégron et de son intermédiaire
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
EP3220942B1 (fr) 2014-11-20 2022-04-27 Serenity Pharmaceuticals LLC Compositions comprenant de la desmopressine a faible dose combinée à un antagoniste du récepteur alpha-adrénergique
CN104496841B (zh) * 2014-11-26 2017-01-25 南京工业大学 一种米拉贝隆中间体的合成方法
CN104744292A (zh) * 2015-03-11 2015-07-01 南京工业大学 (r)-2-((4-硝基苯乙基)氨基)-2-氧代-1-苯乙基乙酸酯或其衍生物的制备方法
JP2018090490A (ja) * 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
JP6618736B2 (ja) 2015-09-01 2019-12-11 沢井製薬株式会社 ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法
CN106278909B (zh) * 2016-08-12 2022-07-15 浙江华海药业股份有限公司 一种米拉贝隆中间体的后处理方法
EP3489224A1 (fr) 2017-02-14 2019-05-29 Alfred E. Tiefenbacher (GmbH & Co. KG) Promédicaments mirabegron
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
US11123320B2 (en) 2017-05-31 2021-09-21 Sbi Pharmaceuticals, Co., Ltd. Prophylactic or therapeutic agent for hyperaciive bladder
AU2018282104B2 (en) 2017-06-06 2024-07-11 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
WO2019013583A2 (fr) 2017-07-14 2019-01-17 주식회사 대웅제약 Préparation pharmaceutique et son procédé de préparation
KR101937713B1 (ko) 2017-07-14 2019-01-14 주식회사 대웅제약 약제학적 제제 및 그 제조방법
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
EP3722285B1 (fr) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Procédé de préparation de mirabegron énacarbile
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법
EP4338729A1 (fr) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé comprenant du mirabegron
EP4410279A1 (fr) 2023-01-25 2024-08-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Comprimé de film comprenant du mirabegron
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07119189B2 (ja) 1989-09-28 1995-12-20 北陸製薬株式会社 光学活性なベンジルアルコール誘導体及びその用途
GB9107827D0 (en) 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH06293664A (ja) 1993-04-05 1994-10-21 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
AU6581294A (en) 1993-04-26 1994-11-21 Fujisawa Pharmaceutical Co., Ltd. Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
JPH07228543A (ja) 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
HUP9802318A3 (en) 1995-10-26 2001-04-28 Mitsubishi Tokyo Pharm Inc Phenylethanolamine derivatives, process for producing the same, and intermediates in the production of the same
US6204285B1 (en) * 1996-07-01 2001-03-20 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate
CA2263659A1 (fr) 1996-08-19 1998-02-26 Kissei Pharmaceutical Co., Ltd. Remede therapeutique ou preventif contre l'incontinence ou l'elimination urinaire frequente
US6630515B2 (en) * 1997-08-28 2003-10-07 Afferon Corporation Urinary incontinence therapy
PT1028111E (pt) * 1997-10-17 2004-09-30 Yamanouchi Pharma Co Ltd Derivados de amida ou seus sais
DE69818516T2 (de) 1997-12-18 2004-07-08 Kissei Pharmaceutical Co., Ltd., Matsumoto Phenylaminoalkylcarbonsäure-derivate und medizinische zusammensetzungen, die diese enthalten
DE69919860T2 (de) 1998-04-14 2005-08-25 Kissei Pharmaceutical Co., Ltd., Matsumoto 2-methylpropionsäure-derivate und sie enthaltende medizinische zubereitungen
MY126489A (en) 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
WO2000047771A2 (fr) 1999-02-12 2000-08-17 Genset Marqueurs bialleles derives de regions genomiques porteuses de genes intervenant dans le metabolisme de l'acide arachidonique
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
JP2001114736A (ja) 1999-10-19 2001-04-24 Kissei Pharmaceut Co Ltd ２−アミノプロパノール誘導体
CA2398199A1 (fr) 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha Nouveaux agents therapeutiques utilisant un agoniste .beta.3
AUPQ585000A0 (en) 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
EP1879578A4 (fr) 2005-03-21 2009-05-13 Dov Pharmaceutical Inc Methodes et compositions destinees au traitement de l'incontinence urinaire

Also Published As

Publication number Publication date
LU92218I2 (fr) 2014-01-07
NO2015001I2 (no) 2015-01-26
AU2003284700B2 (en) 2009-05-28
NZ539577A (en) 2007-06-29
JPWO2004041276A1 (ja) 2006-03-02
PT1559427E (pt) 2011-05-27
WO2004041276A1 (fr) 2004-05-21
NO334948B1 (no) 2014-08-04
CA2503570C (fr) 2011-04-19
HUS1300027I1 (hu) 2016-08-29
FR13C0032I2 (fr) 2014-03-07
CY2013023I1 (el) 2015-10-07
RU2005117367A (ru) 2006-01-20
EP1559427B1 (fr) 2011-03-09
DE60336334D1 (de) 2011-04-21
RU2321401C2 (ru) 2008-04-10
US7750029B2 (en) 2010-07-06
USRE44872E1 (en) 2014-04-29
US20090093529A1 (en) 2009-04-09
CN1711085A (zh) 2005-12-21
MXPA05004925A (es) 2005-08-18
CA2503570A1 (fr) 2004-05-21
KR100967070B1 (ko) 2010-07-01
ES2360353T3 (es) 2011-06-03
ATE500827T1 (de) 2011-03-15
NO20052691D0 (no) 2005-06-06
JP3815496B2 (ja) 2006-08-30
BR0316080A (pt) 2005-09-27
IL168121A (en) 2011-12-29
NO2015001I1 (no) 2015-01-19
NL300599I2 (fr) 2017-01-03
CN100406011C (zh) 2008-07-30
US20060115540A1 (en) 2006-06-01
NO20052691L (no) 2005-07-15
FR13C0032I1 (fr) 2013-08-09
CY2013023I2 (el) 2015-10-07
EP1559427A1 (fr) 2005-08-03
DK1559427T3 (da) 2011-04-26
PL376771A1 (pl) 2006-01-09
BE2013C040I2 (fr) 2023-03-07
CY1111399T1 (el) 2015-08-05
US8835474B2 (en) 2014-09-16
ZA200503510B (en) 2006-12-27
SI1559427T1 (sl) 2011-06-30
US20110230530A1 (en) 2011-09-22
EP1559427A4 (fr) 2007-05-30
KR20050072809A (ko) 2005-07-12
PL211687B1 (pl) 2012-06-29
AU2003284700A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
BE2013C040I2 (fr)
DE60024946D1 (de) Elektrodengürtel eines Herzfrequenzüberwachungsgerätes
EA200100826A1 (ru) 16-галогенопроизводные эпотилона, способ их получения и их применение в фармацевтике
WO2002085861A8 (fr) Composes d'imidazolidine et leur utilisation comme antagonistes de cxcr3
NO1994007I1 (no) Ketorolac/ 5-benzoyl-1,2-dihydro-3H-pyrrolo-[1,2-a]-pyrrol-1-karboksylsyre og dens farmasøytisk akseptable salter
NO20051892L (no) Ny forbindelse
NO20051893L (no) Ny forbindelse
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
DE69210654D1 (de) Verwendung von Tomoxetine zur Behandlung von Funktionsstörungen der niedrigen Harnwege
BR0213926A (pt) método e disposição para a fabricação de um produto de ácido percarboxìlico
ITMI20001051A0 (it) Formulazioni contenenti un farmaco glucocorticosteroide per il trattamento di patologie broncopolmonari
DE60021013D1 (de) Überwachung der Narkosetiefe eines Patienten
CN2417896Y (zh) 用于构成木人桩的围带式活动桩肢
DE60007548D1 (de) Omega kettenmodifizierte hydroxyeicosatetraensäure derivate verwendbar in der behandlung der "trockenes auge" krankheit
ES531572A0 (es) Procedimiento de preparacion de polimetileno iminas disustituidas
GB2000510A (en) Therapeutic Dipeptides
LV11524A (lv) Benzidamina izmantosana TNF izsaukto patologisko stavoklu arstesana
ITMI20021168A1 (it) Procedimento per la preparazione dell'acido (s)-tetraidro-a-(1-metiletil)-2-osso-1(2h)-piridinacetico
LV12781B (lv) Skidro kristalu pildvielu saturosas dermatologiskas kompozicijas un metode to iegusanai
ITMI20020974A1 (it) Procedimento per la preparazione dell'acido 4-fluoro-antranilico
ITMI20000376A0 (it) Allomorfo del cloridrato dell'isomero z di derivato di alchilamminofurano procedimento per la sua produzione e composizione farmaceutica che
WO2002056870A3 (fr) Methode de traitement de troubles du sommeil
WO2005097113A3 (fr) Antagonistes du recepteur de la 5-ht2b
SE9601142D0 (sv) Golfklubba med kompensation för golfbollens högervridning resp vänstervridning vid utslaget
ITBO20020357A1 (it) Apparecchiatura per la valutazione morfologica dell ' apparato muscolare